Meeting
2017 ASCO Annual Meeting
Preliminary results from the international neoadjuvant melanoma consortium (INMC).
Authors
Alexander M. Menzies
Melanoma Institute Australia, Royal North Shore Hospital, The University of Sydney, Sydney, Australia
Alexander M. Menzies , Elisa A. Rozeman , Rodabe Navroze Amaria , Richard A. Scolyer , Michael T. Tetzlaff , Alexander Guminski , Michael A. Davies , Christian U. Blank , Jennifer Ann Wargo , Georgina V. Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02437279, NCT02231775, NCT02519322, NCT01972347
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9581)
DOI
10.1200/JCO.2017.35.15_suppl.9581
Abstract #
9581
Poster Bd #
189
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.
First Author: Judith M. Versluis
Poster
2022 ASCO Annual Meeting
The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
First Author: Minke W. Lucas
Poster
2016 ASCO Annual Meeting
Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma.
First Author: Robyn Saw
Poster
2015 ASCO Annual Meeting
Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma.
First Author: Jennifer Ann Wargo